So-Young International Inc. — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 report; the filing does not provide a clear standalone Q4 financial summary. Financial statements are prepared under U.S. GAAP. Amounts below are RMB millions unless stated otherwise.
Business context
So-Young operates a China-focused online medical aesthetics and consumption-healthcare platform. It provides information and marketing services to providers and earns reservation fees on treatments booked through its platform. The company says it is expanding into areas including dental, dermatology, ophthalmology, gynecology, and physical examinations.
Key financial metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | 1,295.0 (US$198.5m) | 1,151.6 | +12.4% |
| Information-services revenue | 962.1 | 833.4 | +15.4% |
| Reservation-services revenue | 332.9 | 318.2 | +4.6% |
| Gross profit / margin | 1,082.8 / 83.6% | 953.0 / 82.8% | Profit +13.6%; margin +0.8 percentage points |
| Operating expenses | 1,139.5 | 807.8 | +41.0% |
| Operating income (loss) / margin | (56.7) / (4.4%) | 145.2 / 12.6% | Shifted to operating loss |
| Net income | 4.9 | 176.7 | Down 97.2% |
| Net income attributable to So-Young | 5.8 | 176.7 | Down substantially |
| Operating cash flow | 179.2 | 383.8 | Down 53.3% |
| Cash, cash equivalents and restricted cash at year-end | 1,145.7 | 901.2 | Up 27.1% |
At December 31, 2020, current assets were RMB2,796.0m and current liabilities were RMB570.9m. Term deposits and short-term investments totaled RMB1,527.1m. Total liabilities were RMB672.4m, including operating lease liabilities of RMB132.5m. The company repaid RMB6.5m of short-term borrowing during 2020; the filing does not indicate material outstanding conventional borrowings. Management said available cash and anticipated operating cash flows should cover working-capital requirements and capital expenditures for at least 12 months.
Total comprehensive loss was RMB139.3m, driven principally by a RMB144.2m foreign-currency translation loss. The net income tax benefit was RMB4.8m; management attributed it in part to a change in a subsidiary’s preferential tax rate and a RMB16.4m refund of prior-period taxes.
Material changes versus FY2019
- Revenue growth slowed to 12.4% from 86.6% in 2019. Average mobile MAUs rose 144.8% to 7.1m, while purchasing users increased only 6.0% to 601,800.
- Paying medical-service providers increased 26.3% to 5,570, but average revenue per paying provider declined 10.8%.
- COVID-19 disrupted operations and reduced surgical transactions. Purchasing users declined 39.1% in Q1 and 15.1% in Q2 2020, as compared with the corresponding prior-year quarters.
- Sales and marketing expense rose 54.5% to RMB726.3m, including substantially higher branding and marketing spending. Research and development expense rose 29.3% to RMB229.2m. These increases contributed to the operating loss despite higher revenue and gross profit.
- Operating cash flow fell to RMB179.2m. Investing activities provided RMB123.8m, largely reflecting investment and term-deposit maturities; financing activities used RMB5.8m.
Outlook, commentary, risks and unusual items
- Outlook: No numerical revenue or earnings guidance is provided. Management described its strategy as focused on user growth, content and platform development, provider monetization, and expansion into broader healthcare services. It expects sales and marketing expenses to grow in the foreseeable future and said it believed the company was positioned for sustainable growth when normal operating conditions return.
- COVID-19: The company warned that continued or renewed restrictions could further affect revenues, provider operations and payments, user activity, and long-term investments. The extent and duration of effects could not be reasonably estimated in the filing.
- Acquisitions and investments: In October 2020, So-Young acquired 63.37% of online dental-platform operator Leya for cash consideration of RMB41.8m and recognized RMB48.5m of goodwill and RMB20.5m of identifiable intangible assets. It also invested RMB125m in a 15.1% interest in Shanghai Linkedcare. In March 2021, it agreed to acquire an entity holding a microfinance license and had prepaid RMB115m; the filing says consideration would equal net asset book value plus RMB30m.
- Legal matters: The company disclosed 22 pending platform-related intellectual-property lawsuits at December 31, 2020, with approximately RMB4.3m in aggregate damages sought. It reported RMB11.4m paid or payable from settlements or adverse judgments in such lawsuits during 2018–2020. Management said it was not aware of pending or threatened proceedings likely to have a material adverse effect.
- Regulatory and structural risks: The company operates in China through contractual VIE arrangements rather than direct ownership of key operating entities. It disclosed uncertainty over future treatment of VIEs and foreign investment rules, and that it lacked certain permits that could be required for some content or services, including an Audio-Visual License and potentially an Internet Publishing License. Medical-advertising classification, provider qualification, consumer-health claims, and data privacy are also significant risks.
- Other risks: The filing highlights China regulatory change, foreign-exchange and fund-transfer controls, competition, consumer and provider claims, and potential U.S. trading restrictions if the PCAOB cannot inspect the company’s China-based auditor. The company reported that its auditor attested to effective internal control over financial reporting as of year-end 2020 and that a previously identified material weakness had been remediated; Leya was excluded from the internal-control assessment because it was acquired during 2020 and represented less than 1% of relevant consolidated assets and revenue.
Most important facts for investors to verify
- Whether user growth and provider monetization can translate into improved operating profitability, given rising marketing costs and the FY2020 operating loss.
- The persistence of COVID-19 effects, purchasing-user trends, provider payment and collection quality, and the reported decline in revenue per paying provider.
- The terms, performance and potential further funding needs of Leya and other investments, including the microfinance-license transaction and its RMB115m prepayment.
- The status and financial exposure of pending intellectual-property cases, and any developments involving provider vetting, medical advertising, or required licenses.
- The enforceability and regulatory acceptance of the VIE arrangements, and the company’s practical ability to transfer cash from China to the holding company.
- The reconciliation of share counts and equity-plan capacity across the filing, and the potential dilution from outstanding and future awards.
- The liquidity and valuation of term deposits and short-term investments, foreign-currency exposure, and any changes in auditor-inspection or U.S. listing requirements.